BIODELIVERY SCIENCES INTERNATIONAL INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD; shares in millions, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities
Depreciation
Accretion of debt discount and loan costs
Amortization of intangible assets
Provision for inventory obsolescence
Impairment loss on equipment
Deferred income taxes
Bargain purchase gain
Net change in operating lease assets and liabilities
Stock-based compensation expense
Changes in assets and liabilities, net of effect of acquisition:
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable and accrued expenses
Deferred revenue

Net cash flows used in operating activities
Deferred revenue
Net cash flows provided by operating activities
Investing activities:
Product acquisitions
Acquisitions of equipment
Net cash flows used in investing activities
Financing activities:
Proceeds from exercise of stock options
Proceeds from issuance of Series B preferred stock
Payment on note payable
Proceeds from notes payable
Equity finance costs
Payment of deferred financing fees
Net cash flows from financing activities
Loss on refinancing of former debt
Payment on share repurchase
Net cash flows (used in) provided by financing activities

Net change in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Cash paid for interest
Cash paid for income taxes
Non-cash Financing and Investing Activities:
Adjustments to additional paid in capital dividends in excess of retained earnings
Series B Non-Voting Convertible Preferred Stock
Total adjustments to additional paid in capital dividends in excess of retained earnings
Common stock issuance upon retirement (in shares)
Common stock issuance upon retirement
Accrued financing expenses
Series B Non-Voting Convertible Preferred Stock
Total accrued financing expenses

Fair value of bargain purchase price of BELBUCA acquisition
Fair value of warrants, in connection with CRG term loan

Comments